Zealand Pharma Shares Drop 12% as Obesity Drug Trial Flags High Discontinuation Rate

Shares in Zealand Pharma (ZELA) fell by as much as 12.5% on Thursday after the company released mixed results from a late-stage trial of its obesity drug candidate, survodutide. While the drug achieved its primary goals for weight loss, investors focused on a high rate of patients who stopped treatment due to side effects, raising concerns about its commercial viability.

Trial Results Show Efficacy and Tolerability Concerns

The Phase III SYNCHRONIZE-2 trial, which involved 755 overweight or obese adults with type 2 diabetes, met its main endpoints. According to Zealand, the 76-week study showed that patients taking survodutide experienced significant body weight reduction.

However, the data also highlighted a significant tolerability issue. Key findings from the trial include:

• Weight Loss: Patients lost up to an average of 13.1% of their body weight, compared to a 3.1% loss in the placebo group.
• Discontinuation Rate: 18% of patients receiving survodutide discontinued the treatment due to gastrointestinal side effects, a stark contrast to the 1.2% rate in the placebo group.
• Blood Sugar Control: The drug also reduced average HbA1c levels, a key measure of blood sugar, by up to 1.21 percentage points.

The company noted that the most common side effects were nausea, vomiting, diarrhea, and constipation, which were described as mostly mild to moderate. Most discontinuations occurred during the dose-escalation phase of the trial.

Market Impact and Competitive Landscape

Ad

The sharp decline in Zealand Pharma's share price underscores investor sensitivity to the side-effect profiles of new weight-loss drugs. In the highly competitive and lucrative obesity market, a drug's ability to be tolerated by patients is as critical as its effectiveness. A high dropout rate could limit survodutide's potential to compete with established and emerging treatments.

The results present a challenging trade-off between strong efficacy and patient tolerability, which will be a key factor in the drug's future regulatory and commercial pathway. Survodutide is a dual-action drug targeting both GLP-1 and glucagon receptors, a mechanism aimed at enhancing weight loss.

Context and Next Steps

Survodutide is licensed by Zealand to Boehringer Ingelheim, which is managing its global development and commercialization. The drug's safety and effectiveness have not yet been established by regulatory authorities.

Boehringer Ingelheim is conducting additional Phase III trials, including one focused on blood sugar control in people with type 2 diabetes. Zealand also stated that results from a separate cardiovascular outcomes trial are anticipated later this year, which will provide a more complete picture of the drug's overall profile.